Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: Results of an online tumor registry of clinical trials Academic Article uri icon

Overview

MeSH Major

  • Carcinoma, Non-Small-Cell Lung
  • Clinical Trials as Topic
  • Lung Neoplasms
  • Proto-Oncogene Proteins
  • Receptor, Epidermal Growth Factor
  • Registries
  • ras Proteins

abstract

  • EGFR mutation status is associated with sensitivity to treatment with an EGFR-TKI in patients with advanced non-small cell lung cancer. Patients harboring sensitizing EGFR mutations should be considered for first-line erlotinib or gefitinib.

publication date

  • August 15, 2009

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC3219530

Digital Object Identifier (DOI)

  • 10.1158/1078-0432.CCR-09-0888

PubMed ID

  • 19671843

Additional Document Info

start page

  • 5267

end page

  • 73

volume

  • 15

number

  • 16